Home > News > Abraxis BioScience splits in two
July 5th, 2007
Abraxis BioScience splits in two
Abstract:
The new Abraxis BioScience would become a more highly focused biotechnology company, which would concentrate more on the nab (nanoparticle-albumin bound) technology platform to deliver therapeutics, such as ABRAXANE (albumin-bound paclitaxel), and work towards new and personalized treatments to patients with life-threatening diseases, Soon-Shiong said.
Source:
biopharma-reporter.com
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||